VRX.TO - Valeant Pharmaceuticals International, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
20.99
+0.53 (+2.59%)
As of 12:32PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close20.46
Open20.53
Bid20.99 x 0
Ask21.00 x 0
Day's Range20.40 - 21.45
52 Week Range11.20 - 23.75
Volume1,259,191
Avg. Volume1,477,507
Market Cap7.343B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-3.27
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.71
  • Valeant Closes Senior Note Offering, Reprices Term Loan
    Zacks4 hours ago

    Valeant Closes Senior Note Offering, Reprices Term Loan

    Valeant (VRX) offered new debt and restructured old debt. The company is making efforts to repay its huge level of debt.

  • CNW Group21 hours ago

    Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment

    Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment

  • PR Newswire21 hours ago

    Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment

    LAVAL, Quebec , Nov. 21, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") announced today that it has closed its ...

  • Can Valeant (VRX) Turn Around on Rebuilding Initiatives?
    Zacksyesterday

    Can Valeant (VRX) Turn Around on Rebuilding Initiatives?

    Valeant (VRX) has performed much better so far in 2017 compared to last year on the back of rebuilding initiatives.

  • PR Newswireyesterday

    Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

    LAVAL, Quebec , Nov. 21, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen , executive vice president, ...

  • SmarterAnalyst5 days ago

    Deutsche Bank Pinpoints Uncertainties Nipping at Valeant’s Potential for Growth

    Valeant Pharmaceuticals (NYSE:VRX) aced its third quarter, but while many on Wall Street were thrilled to see the biotech giant take a stride forward after quite a volatile year, better risk/reward is not enough to sway Deutsche Bank analyst Gregg Gilbert from the sidelines. What has left Gilbert cautiously optimistic on the company's recovery, but dialing down his price target?

  • Reuters6 days ago

    LPC: US loan issuers lean on bond market to refinance parts of jumbo loans

    US companies with rocky histories in the leveraged loan market, including vitamin and supplement retailer GNC Holdings Inc, weight loss company Weight Watchers International and specialty drug maker Valeant Pharmaceuticals International, are turning to the high-yield bond market to help refinance large existing loans, sources said. The bond market generally offers eight- to 10-year maturities while the loan market offers six- or seven-year tenors. GNC is attempting to refinance for the second time this year after a previous loan market attempt failed in May. The company cancelled its deal after investors asked for higher pricing to compensate for the risk associated with lending to a ‘brick and mortar’ retailer.

  • Barrons.com6 days ago

    Valeant: Tempting? Sure. But It Might Not Be a Buy Just Yet.

    Yup! Things seem to be looking up for Valeant Pharmaceuticals International (VRX). The drug maker reported third quarter per-share profit that blew past expectations, albeit lowered expectations. Moody’s ...

  • PR Newswire6 days ago

    TroyGould Advises Haitong International in its $190 Million Acquisition of Obagi Skincare Products Business

    LOS ANGELES , Nov. 16, 2017 /PRNewswire/ --  TroyGould advised Haitong International Zhonghua Finance Acquisition Fund I, L.P. (the "Fund") in its $190 million cash acquisition of the Obagi Medical ...

  • PR Newswire7 days ago

    Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program

    LAVAL, Quebec, Nov. 15, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, today announced that its unique ONE by ONE Recycling Program has recycled a combined total of more than one million used contact lenses, blister packs and top foils in less than one year since its launch. Made possible through a collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste, the ONE by ONE Recycling Program has diverted more than 7,000 pounds of waste from landfills. "We are globally committed to environmental sustainability while also delivering innovations that meet the needs of our physicians and their patients," said Joseph C. Papa, chairman and CEO, Valeant.

  • MarketWatch7 days ago

    Valeant is providing the media with an earnings metric that the SEC told it to stop using

    Valeant Pharmaceuticals International Inc. has been directed by the Securities and Exchange Commission to clean up its use of nonstandard numbers, but the company is now sending one number to reporters ...

  • Motley Fool8 days ago

    Is Valeant Turning Things Around?

    With a new CEO, Valeant seems to be trying to recover from their 2015 debacle, but will the company be able to pull it off?

  • PR Newswire8 days ago

    Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes

    LAVAL, Quebec, Nov. 14, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of its 5.500% senior secured notes due 2025 (the "Notes"). The Notes will be additional notes and form part of the same series as Valeant's existing 5.500% senior secured notes due 2025. Valeant intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repay (on a pro rata basis) a portion of its outstanding Series F Tranche B Term Loan Facilities due 2022 and to pay related fees and expenses.

  • CNW Group8 days ago

    Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes

    Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes

  • SmarterAnalyst8 days ago

    BMO Wonders If Valeant Can Keep Up Its Growth Momentum in Key Franchises

    Valeant Pharmaceuticals (NYSE:VRX) has attracted a great deal of positive Street buzz after last Tuesday's posted third quarter beat. BMO analyst Gary Nachman is out with a cautiously optimistic bumping up his price target a dollar. Yet, it is not all clear, cloudless skies for the biotech giant quite yet. Why is Nachman cautious?

  • PR Newswire8 days ago

    Ortho Dermatologics Announces Aspire Higher Scholarship Honorees

    "Since 2013, the Ortho Dermatologics Aspire Higher Scholarship program has recognized students that have not allowed skin conditions like psoriasis, eczema and severe acne to stand in the way of their academic achievements. Three scholarships were awarded in each of three categories: Undergraduate Scholar Awards for students pursuing an undergraduate degree, Graduate Scholar Awards for students pursuing a graduate degree and Today's Woman Scholar Awards for students who are mothers pursuing higher education.

  • TheStreet.com9 days ago

    Valeant Stock Tumbles on $750 Million Debt Offering Announcement

    The notes are due in 2025. Proceeds from the offering will help pay down some of Valeant's more than $26 billion debt load.

  • Barrons.com9 days ago

    Valeant: Is the Rally Over?

    Last week, Valeant Pharmaceuticals International (VRX) rallied after the drug maker unveiled an estimate-beating earnings report that reassure investor that it was making progresses rebuilding itself after following a series of investigations into the drug maker’s accounting and pricing practices. Also helping fuel the upswing, Valeant reduced its total debt by $6 billion since the first quarter of 2016. Today, the shares are pulling back following Valeant’s launch of a $750 million debt offering.

  • Capital Cube9 days ago

    ETFs with exposure to Valeant Pharmaceuticals International, Inc. : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Valeant Pharmaceuticals International, Inc. Here are 5 ETFs with the largest exposure to VRX-CA. Comparing the performance and risk of Valeant Pharmaceuticals International, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • SmarterAnalyst9 days ago

    Valeant 3Q Beat Has Not Swayed Wells Fargo from Sounding the Alarm

    Valeant Pharmaceuticals (NYSE:VRX) has gotten some of the Street excited after a much-needed third quarter beat to re-ignite confidence after a string of litigations and investigations came to haunt the giant. Yet, what makes Wells Fargo analyst David Maris dismiss market enthusiasm as overblown?

  • MarketWatch9 days ago

    Valeant issues $750 million in debt to pay down debt

    Valeant Pharmaceuticals International Inc. said Monday it was launching a private offering of $750 million worth of notes due 2025, paying 5.500%. The drug maker plans to use the proceeds from the debt ...

  • CNW Group9 days ago

    Valeant Announces Launch of Private Offering of Add-On Secured Notes

    Valeant Announces Launch of Private Offering of Add-On Secured Notes

  • PR Newswire9 days ago

    Valeant Announces Launch of Private Offering of Add-On Secured Notes

    LAVAL, QUEBEC, Nov. 13, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant" or the "Company") announced today that it has launched an offering of $750,000,000 aggregate principal amount of 5.500% senior secured notes due 2025 (the "Notes"). The Notes will be additional notes and form part of the same series as Valeant's existing 5.500% Senior Secured Notes due 2025. Valeant intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repay (on a pro rata basis) a portion of its outstanding Series F Tranche B Term Loan Facilities due 2022, and to pay related fees and expenses.

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of VRX.TO earnings conference call or presentation 7-Nov-17 1:00pm GMT

    Q3 2017 Valeant Pharmaceuticals International Inc Earnings Call

  • MarketWatch10 days ago

    Weekend roundup: Valeant’s earnings games | Tesla’s junk | How Apple stashes cash

    Here are MarketWatch articles to read this weekend.